“The existing scenario has uncovered some structural weaknesses within the EU’s medicines offer chain and a substantial dependence on non-EU countries for active pharmaceutical ingredients,” Kyriakides explained. She suggested that supply chain troubles be dealt with within an EU pharmaceutical method envisioned to become launched by the end